• Measuring Cancer Drug Responses Beyond Viability

  2026-08-09

  Hannah R. Schwartz’s 2022 dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central contribution is a framework that separates proliferative arrest from cell killing and emphasizes their distinct proportions and timing, improving interpretation of in vitro pharmacology.

• Chemistry of Silybin: Structure and Derivatives

  2026-08-08

  Křen and colleagues provide a detailed chemistry-focused review of silybin, the principal flavonolignan associated with milk thistle extract. Its central contributions are the clarification of silybin A and B stereochemistry, the development of separation strategies, and a systematic account of derivatives relevant to solubility, activity, and mechanistic research.

• GI 254023X: ADAM10 Inhibitor Workflows

  2026-08-07

  GI 254023X gives researchers a selective way to connect ADAM10 sheddase activity with Notch1 signaling, Jurkat-cell responses, and endothelial barrier protection. This practical guide combines assay design, dose and solvent controls, cross-domain interpretation, and troubleshooting for more reproducible preclinical studies.

• Dibutyryl-cAMP, Sodium Salt: Data-Driven Solutions for Cell

  2026-08-07

  This scenario-driven guide explores how Dibutyryl-cAMP, sodium salt (SKU B9001) addresses persistent challenges in cell viability, proliferation, and signaling assays. Drawing on quantitative literature and validated best practices, it offers actionable insights for biomedical researchers seeking reliable, reproducible cAMP pathway modulation.

• Forskolin: Adenylate Cyclase Activator for Advanced Cell Ass

  2026-08-06

  Forskolin stands out as a precise adenylate cyclase activator, empowering reproducible cAMP pathway modulation in stem cell and neuroendocrine models. Explore optimized experimental workflows, troubleshooting tactics, and translational insights that set Forskolin apart for both bench and preclinical research.

• Ferroptosis-Gene Signature Predicts HCC Prognosis, Atorvasta

  2026-08-06

  This study establishes a novel prognosis model for hepatocellular carcinoma (HCC) using ferroptosis-related genes and demonstrates that atorvastatin, a known HMG-CoA reductase inhibitor, induces ferroptosis and suppresses HCC cell proliferation and migration. The findings support both biomarker-driven risk stratification and targeted therapy development in liver cancer research.

• Catalpol’s Neuroprotective Mechanisms in Alzheimer’s Disease

  2026-08-05

  The referenced study comprehensively reviews catalpol’s multi-target neuroprotective effects, highlighting its antioxidant, anti-inflammatory, and antiapoptotic actions in Alzheimer’s disease models. These findings support the growing interest in natural product-based interventions for neurodegenerative disorders, with implications for translational research targeting inflammation and metabolic dysfunction.

• CNQX (SKU B6222): Reliable Inhibitor for Glutamatergic Assay

  2026-08-05

  This article provides practical, scenario-driven guidance for leveraging CNQX (SKU B6222) as a selective glutamatergic neurotransmission inhibitor. By addressing real laboratory challenges—from experimental design to vendor selection—it demonstrates how CNQX enhances assay reproducibility and sensitivity, grounded in recent evidence and validated protocols.

• BH3 Mimetics Clear Senescent Cells in TP53 Wild-Type Breast

  2026-08-04

  Ungerleider et al. reveal that BH3 mimetics targeting BCL-XL and MCL1 selectively eliminate chemotherapy-induced senescent breast cancer cells, improving tumor regression and survival in TP53 wild-type models. This mechanistic insight underscores the therapeutic promise of BCL-XL inhibition to overcome persistent residual disease after chemotherapy.

• Omeprazole (A2845) for Reliable H+,K+-ATPase Inhibition Stud

  2026-08-04

  Omeprazole (SKU A2845) is a high-purity H+,K+-ATPase inhibitor, supporting robust research on gastric acid secretion and antiulcer mechanisms. This reagent is not designed for diagnostic or therapeutic use, and should be applied exclusively in controlled laboratory workflows requiring validated potency and selectivity.

• Tamsulosin in Urological Disease Research: Protocols and Ins

  2026-08-03

  Tamsulosin, a selective α₁A-adrenergic receptor antagonist, is transforming urological and smooth muscle research with reliable performance in both clinical and experimental settings. Learn how to optimize protocols and troubleshoot common challenges, backed by the latest meta-analytic evidence and APExBIO’s rigorously characterized compound.

• Spleen-Targeted Neoantigen mRNA Vaccine Induces TLS in HCC

  2026-08-03

  Lin et al. introduce a spleen-targeted neoantigen mRNA vaccine (STNvac) that robustly activates ISG15+ CD8+ T cells and promotes tertiary lymphoid structure formation in hepatocellular carcinoma. This study uncovers new mechanistic insights into mRNA vaccine-based immunotherapy for immune-refractory solid tumors, with implications for the rational design of next-generation cancer vaccines.

• RG7388 MDM2 Antagonist: Applied Protocols & Tumor Model Insi

  2026-08-02

  RG7388, a highly selective MDM2 antagonist supplied by APExBIO, enables robust p53 pathway activation and reproducible cancer cell apoptosis induction in wild-type p53 tumor models. This guide unpacks practical assay workflows, optimization strategies, and evidence-driven use-cases—including combination therapy paradigms and troubleshooting tips.

• BAY-826: Potent Small Molecule Inhibitor in Retinal Research

  2026-08-01

  BAY-826 empowers researchers to dissect neurovascular signaling with unrivaled selectivity and reproducibility, making it indispensable for angiopoietin and pigment epithelium-derived factor (PEDF) pathway studies. Its ultra-low nanomolar potency and optimized handling protocols accelerate troubleshooting and enhance experimental clarity in retinal neuron survival assays.

• Estradiol-ERα Inhibits ER Stress to Restore CD4+ T Cells Aft

  2026-07-31

  This study demonstrates that 17β-estradiol restores splenic CD4+ T lymphocyte function after hemorrhagic shock by inhibiting endoplasmic reticulum stress via ERα and GPR30, but not ERβ. The findings clarify receptor-specific immune restoration mechanisms and inform future research on endocrine modulation and trauma-induced immunosuppression.

15127 records 1/1009 page Next 12345 下5页 Last page